OKYO Pharma reports 'statistical significance' achieved in Phase 2 trial of OK-101 in dry eye diseaseProactive Investors • 01/08/24
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024GlobeNewsWire • 01/05/24
OKYO Pharma on track as last patient enrolled in trial to treat dry eye disease completes final protocol visitProactive Investors • 12/04/23
OKYO Pharma files IND application OK-101 to treat Neuropathic Corneal PainProactive Investors • 10/09/23
OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)GlobeNewsWire • 10/09/23
OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary SharesGlobeNewsWire • 09/15/23
OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary SharesGlobeNewsWire • 09/14/23
OKYO Pharma completes enrollment in Phase 2 clinical trial to treat dry eye diseaseProactive Investors • 09/08/23
OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye DiseaseGlobeNewsWire • 09/08/23
OKYO Pharma dry eye disease trial reaches enrollment milestone; topline data expected by year-endProactive Investors • 08/30/23
OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)GlobeNewsWire • 08/30/23
OKYO Pharma makes good progress with flagship OK-101 drug as it wraps up its 2023 financial yearProactive Investors • 08/15/23
OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023GlobeNewsWire • 08/15/23
OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical CenterGlobeNewsWire • 07/28/23
OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating OfficerGlobeNewsWire • 07/27/23